Figure 1.
Figure 1. Progression-free survival in months of evaluable patients treated with IL-12 at a dose of 300 ng/kg or higher.

Progression-free survival in months of evaluable patients treated with IL-12 at a dose of 300 ng/kg or higher.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal